ArticleTranslational oncology2026

The SMAC-mimetic xevinapant differentially enhances cisplatin and immune checkpoint blockade efficacy in high-risk HPV-positive tumors.

Tsung-You Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.